首页> 外文期刊>The Journal of toxicological sciences >Human plasma concentrations of trimethylamine N-oxide extrapolated using pharmacokinetic modeling based on metabolic profiles of deuterium-labeled trimethylamine in humanized-liver mice
【24h】

Human plasma concentrations of trimethylamine N-oxide extrapolated using pharmacokinetic modeling based on metabolic profiles of deuterium-labeled trimethylamine in humanized-liver mice

机译:基于氘 - 肝脏小鼠氘标记的三甲胺的代谢谱,使用药代动力学建模的三甲胺N-氧化物推断的人血浆浓度

获取原文
获取原文并翻译 | 示例
       

摘要

Medicinal carnitine-derived and dietary-derived malodorous trimethylamine and its non-malodorous metabolite trimethylamine N-oxide were historically regarded as nontoxic. Clinical and toxicological interest has recently arisen because of their potential association with atherosclerosis. We previously reported a human physiologically based pharmacokinetic (PBPK) model for trimethylamine and its primary metabolite, trimethylamine N-oxide, based on reported rat trimethylamine pharmacokinetics. However, rats are poor metabolizers with respect to trimethylamine N-oxygenation, and this species difference was investigated in vitro using substrate depletion rates in rat and human liver microsomes. The current study investigated the pharmacokinetics of deuterium-labeled trimethylamine orally administered to immunodeficient humanized-liver mice transplanted with commercially available human hepatocytes. Trimethylamine N-oxide was extensively formed in vivo in humanized-liver mice, but not in control mice. The experimental pharmacokinetic data of deuterium-labeled trimethylamine and its N-oxide in humanized-liver mice were scaled up for application to a human PBPK model. The human plasma concentration curves generated by the resulting simple PBPK model were consistent with concentrations in humans reported in the literature. The model can also simulate human plasma levels of trimethylamine and trimethylamine N-oxide during treatment with the prescription medicine L-carnitine and in trimethylamine loading tests. The predicted plasma levels were in the ranges that occur under the consumption of daily dietary foodstuff; such levels are associated with few toxicological impacts. The present PBPK model for trimethylamine and trimethylamine N-oxide could estimate daily doses by both forward and reverse dosimetry and could facilitate risk assessment in humans.
机译:药用肉碱衍生的和膳食衍生的恶臭三甲胺及其非恶臭代谢物三甲胺N-氧化物历史上被认为是无毒的。最近出现了临床和毒理学利益,因为它们与动脉粥样硬化的潜在联系。我们之前报道了一种用于三甲胺的人类生理学的药代动力学(PBPK)模型及其主要代谢物,三甲胺N-氧化物,基于报道的大鼠三甲胺药代动力学。然而,大鼠对三甲胺N-氧合不良,并且在大鼠和人肝微粒体中使用基质耗尽率在体外研究该物质差异。目前的研究研究了氘标记的三甲胺的药代动力学口服给予用市售的人肝细胞移植到免疫缺陷的人源化 - 肝小鼠中。三甲胺N-氧化物在人源化 - 肝小鼠体内广泛形成,但不在对照小鼠中。将氘标记的三甲胺的实验药代动力学数据及其在人源性肝小鼠中的N-氧化物进行缩放,以应用于人类PBPK模型。由此得到的简单的PBPK模型产生的人血浆浓度曲线与文献中报道的人类的浓度一致。该模型还可以在用处方药L-肉碱和三甲胺加载试验中模拟三甲胺和三甲胺N-氧化物的人血浆水平。预测的血浆水平在日常膳食食品消耗下发生的范围;这种水平与少量毒理撞击有关。本发明的三甲胺和三甲胺N-氧化物的PBPK模型可以通过前向和反向剂量测定估计日常剂量,并且可以促进人类的风险评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号